Skip Navigation
A portrait of David Cho, Managing Director at Vista Point Advisors

David Cho

Managing Director

David Cho is a Managing Director at Vista Point Advisors. Prior to joining Vista Point Advisors, David was a Senior Analyst in the healthcare investment banking group at Wedbush Securities where he advised companies and financial sponsors on M&A, public and private financings, divestitures, and partnerships. As an investment banker, David has executed over 30 transactions with an aggregate deal value of more than $2 billion. David was also a Product Manager at Zynga where he worked on strategy, execution, and marketing for Zynga’s top social games. David received a B.S. in Business Administration from the Haas School of Business at UC Berkeley.

Sell-side Transactions

  • The majority recapitalization of PublicRelay by Tritium Partners
  • The sale of Pear Deck to GoGuardian, a Sumeru Equity Partners Company
  • The sale of Service Fusion to EverCommerce, a PSG and SIlver Lake company
  • The sale of Nymity to TrustArc, a Bregal Sagemount Company
  • The majority recap of Appspace by LLR Partners
  • The sale of Freckle Education to Renaissance, a Francisco Partners Company
  • The sale of Rental History Reports and Trusted Employees to MRI, a TA Associates and GI Partners Company
  • The majority recapitalization of GoGuardian from Sumeru Equity Partners
  • The sale of LogoMix to Deluxe
  • The majority recapitalization of MediaRadar from Frontier Capital
  • The sale of Thinkbox Software to Amazon
  • The sale of Scenario Learning to Vector Solutions, a Providence Equity Company
  • The sale of NaturalPoint to Planar Systems (Leyard)
  • The sale of Imagine Easy Solutions to Chegg
  • The minority investment in Cyara by PeakSpan Capital
  • The sale of Tweak Software to Autodesk
  • The majority recapitalization of GolfLogix Technologies from Emigrant Capital
  • The sale of Linx Technologies to Alpine Investors
  • The sale of Nfocus Neuromedical to Covidien
  • Durata Therapeutics IPO
  • Intercept Pharmaceuticals IPO
  • Cardica follow-on stock offerings